drugset / Trial / NCT04623086
Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of degludec.
Timeline
- Start
- 2020-02-14
- Primary completion
- 2022-09-07
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | insulin degludec | Protein / enzyme biologic | — | Subcutaneous |
| Subject | insulin glargine | Protein / enzyme biologic | — | Subcutaneous |